Abstract
Purpose
Tumor microenvironment consists of various kind of cells, forming complex interactions and signal transductions for tumor growth. Due to this complexity, targeting multiple kinases could yield improved clinical outcomes. In this study, we aimed to investigate the potential of myriocin, from Mycelia sterilia, as a novel dual-kinase inhibitor and suggest myriocin as a candidate for combined chemotherapy.
Methods
We initially evaluated the anti-tumor and anti-metastatic effect of myriocin in mouse allograft tumor models. We examined the effects of myriocin on angiogenesis and tumor vasculature using in vitro, in vivo, and ex vivo models, and also tested the anti-migration effect of myriocin in in vitro models. Next, we explored the effects of myriocin alone and in combination with cisplatin on tumor growth and vascular normalization in mouse models.
Results
We found that myriocin inhibited tumor growth and lung metastasis in mouse allograft tumor models. Myriocin induced normalization of the tumor vasculature in the mouse models. We also found that myriocin suppressed angiogenesis through the VEGFR2/PI3K/AKT pathway in endothelial cells (ECs), as well as cancer cell migration by blocking the IκBα/NF-κB(p65)/MMP-9 pathway. Finally, we found that myriocin enhanced the drug delivery efficacy of cisplatin by increasing the integrity of tumor vasculature in the mouse models, which synergistically increased the anti-tumor activity of cisplatin.
Conclusion
We suggest that myriocin is a novel potent anti-cancer agent that dually targets both VEGFR2 in ECs and IκBα in cancer cells, and exerts more pronounced anti-tumor effects than with either kinase being inhibited alone.
Similar content being viewed by others
Data Availability
The data used to support the findings of this study are included within the article.
References
L. Claesson-Welsh, M. Welsh, J. Intern. Med. 273, 114–127 (2013). https://doi.org/10.1111/joim.12019
C. Fontanella, E. Ongaro, S. Bolzonello, M. Guardascione, G. Fasola, G. Aprile, Ann. Transl. Med. 2, 123 (2014). https://doi.org/10.3978/j.issn.2305-5839.2014.08.14
O. Casanovas, D.J. Hicklin, G. Bergers, D. Hanahan, Cancer Cell 8, 299–309 (2005). https://doi.org/10.1016/j.ccr.2005.09.005
R.K. Jain, Nat. Med. 7, 987–989 (2001). https://doi.org/10.1038/nm0901-987
Y. Huang, S. Goel, D.G. Duda, D. Fukumura, R.K. Jain, Cancer Res. 73, 2943–2948 (2013). https://doi.org/10.1158/0008-5472.CAN-12-4354
G. Gonzalez-Avila, B. Sommer, D.A. Mendoza-Posada, C. Ramos, A.A. Garcia-Hernandez, R. Falfan-Valencia, Crit. Rev. Oncol. Hematol. 137, 57–83 (2019). https://doi.org/10.1016/j.critrevonc.2019.02.010
H. Nagase, R. Visse, G. Murphy, Cardiovasc. Res. 69, 562–573 (2006). https://doi.org/10.1016/j.cardiores.2005.12.002
J.A. DiDonato, F. Mercurio, M. Karin, Immunol. Rev. 246, 379–400 (2012). https://doi.org/10.1111/j.1600-065X.2012.01099.x
K. Taniguchi, M. Karin, Nat. Rev. Immunol. 18, 309–324 (2018). https://doi.org/10.1038/nri.2017.142
N.M. Anderson, M.C. Simon, Curr. Biol. 30, R921–R925 (2020). https://doi.org/10.1016/j.cub.2020.06.081
A. Lachenmayer, S. Toffanin, L. Cabellos, C. Alsinet, Y. Hoshida, A. Villanueva, B. Minguez, H.W. Tsai, S.C. Ward, S. Thung, S.L. Friedman, J.M. Llovet, J. Hepatol. 56, 1343–1350 (2012). https://doi.org/10.1016/j.jhep.2012.01.009
V. Ramakrishnan, M. Timm, J.L. Haug, T.K. Kimlinger, L.E. Wellik, T.E. Witzig, S.V. Rajkumar, A.A. Adjei, S. Kumar, Oncogene 29, 1190–1202 (2010). https://doi.org/10.1038/onc.2009.403
J. Rios-Doria, M. Favata, K. Lasky, P. Feldman, Y. Lo, G. Yang, C. Stevens, X. Wen, S. Sehra, K. Katiyar, K. Liu, R. Wynn, J.J. Harris, M. Ye, S. Spitz, X. Wang, C. He, Y.L. Li, W. Yao, M. Covington, P. Scherle, H. Koblish, Front. Oncol. 10, 598477 (2020). https://doi.org/10.3389/fonc.2020.598477
D.K. Graham, D. DeRyckere, K.D. Davies, H.S. Earp, Nat. Rev. Cancer 14, 769–785 (2014). https://doi.org/10.1038/nrc3847
Y. Miyake, Y. Kozutsumi, S. Nakamura, T. Fujita, T. Kawasaki, Biochem. Biophys. Res. Commun. 211, 396–403 (1995). https://doi.org/10.1006/bbrc.1995.1827
Y.S. Lee, K.M. Choi, M.H. Choi, S.Y. Ji, S. Lee, D.M. Sin, K.W. Oh, Y.M. Lee, J.T. Hong, Y.P. Yun, H.S. Yoo, Cell Prolif. 44, 320–329 (2011). https://doi.org/10.1111/j.1365-2184.2011.00761.x
Y.S. Lee, K.M. Choi, S. Lee, D.M. Sin, Y. Lim, Y.M. Lee, J.T. Hong, Y.P. Yun, H.S. Yoo, Cancer Biol. Ther. 13, 92–100 (2012). https://doi.org/10.4161/cbt.13.2.18870
K.E. Choi, Y.S. Jung, D.H. Kim, J.K. Song, J.Y. Kim, Y.Y. Jung, S.Y. Eum, J.H. Kim, N.Y. Yoon, H.S. Yoo, S.B. Han, J.T. Hong, Arch. Pharm. Res. 37, 501–511 (2014). https://doi.org/10.1007/s12272-013-0315-z
R. Ordonez, A. Fernandez, N. Prieto-Dominguez, L. Martinez, C. Garcia-Ruiz, J.C. Fernandez-Checa, J.L. Mauriz, J. Gonzalez-Gallego, J. Pineal. Res. 59, 178–189 (2015). https://doi.org/10.1111/jpi.12249
V.K. Bhat, E. Bernhart, I. Plastira, K. Fan, N. Ghaffari-Tabrizi-Wizsy, C. Wadsack, G. Rechberger, T. Eichmann, M. Asslaber, I. Spassova, M.E. Verhaegen, E. Malle, J.C. Becker, W. Sattler, J. Invest. Dermatol. 139, 807–817 (2019). https://doi.org/10.1016/j.jid.2018.10.024
P. Zhou, Z. Li, D. Xu, Y. Wang, Q. Bai, Y. Feng, G. Su, P. Chen, Y. Wang, H. Liu, X. Wang, R. Zhang, Y. Wang, Front. Cell. Infect. Microbiol. 9, 225 (2019). https://doi.org/10.3389/fcimb.2019.00225
J.H. Woo, J.H. Lim, Y.H. Kim, S.I. Suh, D.S. Min, J.S. Chang, Y.H. Lee, J.W. Park, T.K. Kwon, Oncogene 23, 1845–1853 (2004). https://doi.org/10.1038/sj.onc.1207307
J.B. Fitzgerald, B. Schoeberl, U.B. Nielsen, P.K. Sorger, Nat. Chem. Biol. 2, 458–466 (2006). https://doi.org/10.1038/nchembio817
E.V. Berdyshev, I. Gorshkova, A. Skobeleva, R. Bittman, X. Lu, S.M. Dudek, T. Mirzapoiazova, J.G. Garcia, V. Natarajan, J. Biol. Chem. 284, 5467–5477 (2009). https://doi.org/10.1074/jbc.M805186200
T. Baumruker, A. Billich, V. Brinkmann, Expert Opin. Investig. Drugs 16, 283–289 (2007). https://doi.org/10.1517/13543784.16.3.283
D. Wang, C.R. Stockard, L. Harkins, P. Lott, C. Salih, K. Yuan, D. Buchsbaum, A. Hashim, M. Zayzafoon, R.W. Hardy, O. Hameed, W. Grizzle, G.P. Siegal, Biotech. Histochem. 83, 179–189 (2008). https://doi.org/10.1080/10520290802451085
L. Dubois, W. Landuyt, K. Haustermans, P. Dupont, G. Bormans, P. Vermaelen, P. Flamen, E. Verbeken, L. Mortelmans, Br. J. Cancer. 91, 1947–1954 (2004). https://doi.org/10.1038/sj.bjc.6602219
A.I. Bachir, A.R. Horwitz, W.J. Nelson and J.M. Bianchini, Cold Spring Harb Perspect Biol 9, a023234 (2017). https://doi.org/10.1101/cshperspect.a023234
Y.A. Komarova, K. Kruse, D. Mehta, A.B. Malik, Circ. Res. 120, 179–206 (2017). https://doi.org/10.1161/CIRCRESAHA.116.306534
S. Spiegel, S. Milstien, Nat. Rev. Mol. Cell Biol. 4, 397–407 (2003). https://doi.org/10.1038/nrm1103
X. Shu, W. Wu, R.D. Mosteller, D. Broek, Mol. Cell. Biol. 22, 7758–7768 (2002). https://doi.org/10.1128/MCB.22.22.7758-7768.2002
Y. Wang, H. Wu, R. Deng, Eur. J. Pharmacol. 910, 174500 (2021). https://doi.org/10.1016/j.ejphar.2021.174500
J. Gavard, J.S. Gutkind, Nat Cell Biol 8, 1223–1234 (2006). https://doi.org/10.1038/ncb1486
M. Rodrigues, X. Xin, K. Jee, S. Babapoor-Farrokhran, F. Kashiwabuchi, T. Ma, I. Bhutto, S.J. Hassan, Y. Daoud, D. Baranano, S. Solomon, G. Lutty, G.L. Semenza, S. Montaner, A. Sodhi, Diabetes 62, 3863–3873 (2013). https://doi.org/10.2337/db13-0014
F. Christian, E.L. Smith and R.J. Carmody, Cells 5, 12 (2016). https://doi.org/10.3390/cells5010012
C.J. Weng, C.F. Chau, Y.S. Hsieh, S.F. Yang, G.C. Yen, Carcinogenesis 29, 147–156 (2008). https://doi.org/10.1093/carcin/bgm261
T. Takahra, D.E. Smart, F. Oakley, D.A. Mann, Int J Biochem Cell Biol 36, 353–363 (2004). https://doi.org/10.1016/s1357-2725(03)00260-7
M. Cully, Nat Rev Drug Discov 16, 87 (2017). https://doi.org/10.1038/nrd.2017.4
C. Jiao, K. Adler, X. Liu, W. Sun, R.F. Mullins, E.H. Sohn, Translat. Vision Sci. Technol. 9, 1–1 (2020)
S. Hong, D.-W. Zheng, C. Zhang, Q.-X. Huang, S.-X. Cheng, X.-Z. Zhang, Sci. Adv. 6, eabb0020 (2020)
F. Bussolino, A. Mantovani, G. Persico, Trends Biochem Sci 22, 251–256 (1997). https://doi.org/10.1016/s0968-0004(97)01074-8
A.A. Abdelghany, E.A. Toraih, A.A. Mohamed, R.M. Lashine, M.H.S. Mohammad, M.S. Nafie, M.S. Fawzy, Ophthalmic Res 64, 261–272 (2021). https://doi.org/10.1159/000511087
F. Shaik, G.A. Cuthbert, S. Homer-Vanniasinkam, S.P. Muench, S. Ponnambalam and M.A. Harrison, Biomolecules 10, (2020) https://doi.org/10.3390/biom10121673
X.L. Chen, J.O. Nam, C. Jean, C. Lawson, C.T. Walsh, E. Goka, S.T. Lim, A. Tomar, I. Tancioni, S. Uryu, J.L. Guan, L.M. Acevedo, S.M. Weis, D.A. Cheresh, D.D. Schlaepfer, Dev Cell 22, 146–157 (2012). https://doi.org/10.1016/j.devcel.2011.11.002
I. Shiojima, K. Walsh, Circ Res 90, 1243–1250 (2002). https://doi.org/10.1161/01.res.0000022200.71892.9f
V.A. Balaji Ragunathrao, M. Anwar, M.Z. Akhter, A. Chavez, Y. Mao, V. Natarajan, S. Lakshmikanthan, M. Chrzanowska-Wodnicka, A.Z. Dudek, L. Claesson-Welsh, J.K. Kitajewski, K.K. Wary, A.B. Malik and D. Mehta, Cell. Rep. 29, 3472–3487 e3474 (2019) https://doi.org/10.1016/j.celrep.2019.11.036
S. Quintero-Fabian, R. Arreola, E. Becerril-Villanueva, J.C. Torres-Romero, V. Arana-Argaez, J. Lara-Riegos, M.A. Ramirez-Camacho, M.E. Alvarez-Sanchez, Front Oncol 9, 1370 (2019). https://doi.org/10.3389/fonc.2019.01370
A. Caretti, A. Bragonzi, M. Facchini, I. De Fino, C. Riva, P. Gasco, C. Musicanti, J. Casas, G. Fabrias, R. Ghidoni, P. Signorelli, Biochim Biophys Acta 1840, 586–594 (2014). https://doi.org/10.1016/j.bbagen.2013.10.018
Y. Wang, N.Y. Park, Y. Jang, A. Ma, Q. Jiang, J Immunol 195, 126–133 (2015). https://doi.org/10.4049/jimmunol.1403149
D.W. Siemann, Cancer Treat. Rev. 37, 63–74 (2011)
S. Chouaib, Y. Messai, S. Couve, B. Escudier, M. Hasmim, M.Z. Noman, Front. Immunol. 3, 21 (2012)
X. Jiang, J. Wang, X. Deng, F. Xiong, S. Zhang, Z. Gong, X. Li, K. Cao, H. Deng, Y. He, J. Exp. Clin. Cancer Res. 39, 1–19 (2020)
S. Azzi, J.K. Hebda, J. Gavard, Front. Oncol. 3, 211 (2013)
D. Ferland-McCollough, S. Slater, J. Richard, C. Reni, G. Mangialardi, Pharmacol. Ther. 171, 30–42 (2017). https://doi.org/10.1016/j.pharmthera.2016.11.008
Y. Shen, S. Li, X. Wang, M. Wang, Q. Tian, J. Yang, J. Wang, B. Wang, P. Liu, J. Yang, J. Exp. Clin. Cancer Res. 38, 427 (2019). https://doi.org/10.1186/s13046-019-1366-x
Funding
This research was supported by National Research Foundation (NRF) grants funded by the Korean government (MSIP) (2017R1A2B3002227 & 2020R1A5A2017323).
Author information
Authors and Affiliations
Contributions
YML directed this project. J-HJ, HJ, SK, and SL designed in vitro and in vivo experiments. J-HJ, UO, HJ, SK, and SL performed the experiments and data analysis. J-HJ, HJ and YML interpreted the data. J-HJ and YML wrote the manuscript.
Corresponding author
Ethics declarations
Ethical approval and Consent to participate
All the animal experiments in the study were conducted according to the Guidelines for Care and Use of Laboratory Animals issued by the Institutional Ethical Animal Care Committee of Kyungpook National University (Protocol number: KNU 2014–0189 and KNU 2017–0145). No any human participants were involved.
Human ethics
Not applicable.
Consent for publication
All authors have agreed to publish this manuscript.
Competing interests
The authors declare no potential conflict of interest.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Jeong, JH., Ojha, U., Jang, H. et al. Dual anti-angiogenic and anti-metastatic activity of myriocin synergistically enhances the anti-tumor activity of cisplatin. Cell Oncol. 46, 117–132 (2023). https://doi.org/10.1007/s13402-022-00737-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13402-022-00737-x